April 7, 2020
Takeda Pharmaceutical and CSL Behring said on April 6 that they have formed an alliance to develop a single, unbranded hyperimmune immunoglobulin therapy for the treatment of patients with serious complications from COVID-19. In line with this move, the Japanese...read more